Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study

  title={Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study},
  author={Eiji Kiyohara and Atsushi Tanemura and Megumi Nishioka and M. Yamada and Aya Tanaka and Akinori Yokomi and Atsuhiro Saito and Kazuma Sakura and Toshihiro Nakajima and Akira Myoui and Toshiharu Sakurai and Yutaka Kawakami and Yasufumi Kaneda and Ichiro Katayama},
  journal={Cancer Immunology, Immunotherapy},
Hemagglutinating virus of Japan (HVJ; Sendai virus) is an RNA virus that has cell fusion activity. HVJ-envelope (HVJ-E) is a UV-irradiated HVJ particle that loses viral replication and protein synthesis activity but retains cell fusion activity. We recently reported that HVJ-E has antitumor effects on several types of tumors. Here, we describe the results of a first-in-human phase I/IIa study in patients with advanced melanoma, receiving intratumoral administration of HVJ-E. The primary aim was… 

Figures and Tables from this paper

A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma
A phase Ia clinical trial of intratumoralGEN0101 administration in six patients with stage IIIC or IV malignant melanoma showed not only the safety and tolerability but also the significant antitumor effect of GEN0101, suggesting that GEN01 01 might be a promising new drug for patients with advanced melanoma.
Hemagglutinating virus of Japan‐envelope containing programmed cell death‐ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma
A non‐replicating virus‐derived vector, hemagglutinating virus of Japan‐envelope (HVJ‐E), is used to inhibit tumor cell PD‐L1 expression by delivering siRNAs to tumor cells and it is believed that this non‐Replicating immunovirotherapy may be a novel therapeutic alternative to treat patients with glioblastoma.
Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma
Molecular features inherent to melanoma are outlined and how this supports the use of viral oncolysis and immunotherapies when used as monotherapie or in combination.
The Innate Immune Signalling Pathways: Turning RIG-I Sensor Activation against Cancer
This paper highlights basic mechanisms of RIG-I signalling in the tumour microenvironment, broadening to the most recent preclinical studies that employ Rig-I agonists and presents an up-to-date selection of clinical trials designed to prove the antitumour role of Rig I and that may result in improved therapeutic outcomes for cancer patients.
Advances in stem cell research and therapeutic development
The scientific rationale, experimental approaches, caveats and results underpinning the clinical use of stem cells in clinic or close to clinical trials are analyzed.
Pim1 kinase positively regulates myoblast behaviors and skeletal muscle regeneration
Mechanistic studies demonstrated that Pim1 kinase interacts with myogenic regulator MyoD and controls its transcriptional activity, inducing the expression of muscle-specific genes, which consequently promotes myogenic differentiation.
Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy
Oncolytic virotherapy (OVT) is a novel type of immunotherapy that induces anti-tumor responses through selective self-replication within cancer cells and oncolytic virus (OV)-mediated


Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application
Several favorable results regarding the antitumor effects of HVJ-E are shown and the novel mechanism underlying this tumor immune response is described, which appears to include not only enhanced effector T cell- and/or natural killer cell-mediated immunity, but also rescue from regulatory T cell (Treg)-mediated immunosuppression.
Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation
It is reported that inactivated, replication-defective Sendai virus particles (HVJ-E) also has an antitumor effect through non-T cell immunity, and injection caused systemic activation of NK cells and enhanced their cytotoxity against tumor cells.
Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients
Intratumoral and subcutaneous injections of HVJ-E are feasible and PSA response was observed in a subgroup of CRPC patients, and tumor immunity and antitumor effect were analyzed.
Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma
HVJ-E enhanced effector T cell-mediated anti-tumor immunity induced by IL-2 through inhibition of Treg-mediated immunosuppression, showing promise as an attractive, novel immunogene therapy for malignant glioma.
A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor
Onco VEXGM-CSF is well tolerated and can be safely administered using the multidosing protocol described, and evidence of an antitumor effect was seen.
Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
This is the first report to show that HVJ-E alone can eradicate tumors and the mechanism through which it induces antitumor immune responses and shows promise as a novel therapeutic for cancer immunotherapy.
Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
Melanoma patients present with elevated levels of Tregs, Ts, and MDSC within established tumors, and direct injection of OncovexGM-CSF induces local and systemic antigen-specific T cell responses and decreases Treg,Ts, andMDSC in patients exhibiting therapeutic responses.
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma
The chemo-immunotherapy approach based on unloaded IFN-DCs injected intratumorally one day after administration of dacarbazine in advanced melanoma was well tolerated, and clinical and immunological responses, including development of vitiligo, were observed, therefore warranting additional clinical studies aimed at evaluating efficacy.
Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system.
HVJ envelope vector will be useful for both ex vivo and in vivo gene therapy experiments, and efficiency of gene transfer was greatly enhanced by protamine sulfate and centrifugation.
Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.
The local delivery of vaccinia virus expressing B7.1 was well tolerated and represents an innovative strategy for altering the local tumor microenvironment in patients with melanoma.